Carregant...
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two pr...
Guardat en:
| Publicat a: | J Oncol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Hindawi
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7201625/ https://ncbi.nlm.nih.gov/pubmed/32411240 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/7131802 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|